Press Release

November 05, 2026 To, To, The Listing Department, The Listing Department BSE Limited, National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (East), Mumbai – 400001 Mumbai – 400051 Scrip code: 544889 Symbol: SYMBIOTEC Subject: Investor Release of Financial Results for the quarter and half year ended September 30, 2026 Dear Sir/Ma’am, We are enclosing herewith the Investor Release being issued by the Company, Symbiotec Pharmalab Limited for the Quarter and half year ended September 30, 2026. The aforesaid information shall also be made available on the website of the Company at https://investor.symbiotec.com/financials?tab=press This is for your Information and Records. Thanking you, For Symbiotec Pharmalab Limited Salil Jain Company Secretary & Compliance Officer Membership No. A41610 Registered Office & Works: Symbiotec Pharmalab Limited (Formerly known as Symbiotec Pharmalab Pvt. Ltd.) 385/2, Pigdamber, Rau, Mhow, Indore - 453331, Madhya Pradesh, India Tel. No.: +91-731-6676405-406 Fax: +91-731-4201222, Email ID : symbiotec@symbiotec.com, Website : www.symbiotec.com CIN: U24232MP2002PLC015293 PRESS RELEASE Symbiotec Pharmalab delivers strong performance with 43% Revenue growth and 169% PAT growth for Q2FY27 on a Y-o-Y basis Indore | November 5th, 2026 Symbiotec Pharmalab Limited (“Symbiotec”), science-driven pharmaceutical and biotechnology company and a global leader in corticosteroid and steroidal-hormone APIs, today announced its unaudited financial results for the quarter & half year ended September 30, 2026. Financial Performance Snapshot Q2 & H1FY27 Particulars Q2FY27 Q2FY26 Y-o-Y H1FY27 H1FY26 Y-o-Y Remarks (Rs. in Crs) API Business • API Gross margins above 60% Operating Revenue 227 196 16% 442 399 11% • API EBIDTA margins steady at ~30% driven by revenue growth and EBIDTA 71 59 21% 137 119 15% favourable sales mix Consolidated Performance Consol. Revenues 280 196 43% 498 399 25% • Milestone based revenue of Rs. 53 crs from Complex Injectables • H1 expenses from new businesses o Opex - Rs. 57 crs incl. ANDA Consol. EBIDTA* 94 50 88% 140 108 29% filling fees o Depreciation - Rs. 24 crs • Revenue generation from various new businesses expected to commence Consol. PAT 52 19 169% 66 49 34% in next 6-12 months *Q2 & H1FY27 excludes one-time IPO expense of ~3 crs Key Operational Highlights APIs Products • Sales growth steady at 11% in H1 FY27 • Successfully completed 4 major regulatory audits recently: o EUGMP audits in Rau and Pithampur plants in March 2026 ▪ Approval certification received for both plants o USFDA audits in H1 FY27 at Rau & Pithampur plants ▪ EIR received for both plants Complex Injectables • Licensing agreement for distribution of two DCV products in US o Agreement signed o Completed milestones invoiced & part revenue of Rs. 53 crs recognized in Q2 FY27 • First molecule ANDA for DCV filed and accepted by USFDA successfully o First generic filing for the DCV product in US market • Filing of second ANDA scheduled for Q4 FY27 o Pre-submission Facility Correspondence (PFC) submitted qualifying for expedited Priority Review Biotech - CDMO Services • Industrial Biotech o 10 years take-or-pay agreement with US based Alternate Protein player in place ▪ Project capex on track o 10 years take-or-pay term sheet with Europe based Alternate Protein player – agreement signing in advanced stages ▪ Initial manufacturing to commence in Q4 • Pharmaceutical : Insulin Drug Substance (DS) o 5 years take-or-pay agreement in place, Capex on track ▪ Filing regulatory approval in Q4 FY27 / Q1 FY28 Capex Update • Total gross capex of approx. Rs. 1,672 crs est by end FY27 o 61% of such total gross capex or Rs. 1,000 Crs invested in new revenue generating businesses o Revenue for majority of new capacities already contracted o Such revenues to commence in the next 6–12 months • H1FY27 gross capex invested ~Rs. 113 crs Net Debt • Net Debt as on 30th Sep 2026 ~Rs. 314 crs Management Commentary Mr. Anil Satwani, Chairman & Managing Director, Symbiotec Pharmalab Limited, said: “Our Q2 FY27 performance reflects strong business momentum, underpinned by the continued progress of our core business and the scaling up of our emerging growth engines. Our API business continues to deliver steady revenue growth of 11% Y-o-Y in H1FY27, driven by healthy volume growth and a favourable product mix. This strong performance in our core business provides a solid foundation as we continue to pursue new opportunities and expand into adjacent growth segments. During the quarter, we signed a Licensing agreement for distribution of two DCV products in the US, for certain completed milestones we have partly recognized revenues in Q2 FY27 and the rest expected to be recognized in the upcoming quarters. Commercial supplies are expected to commence next year, providing an additional boost to our revenue and profitability. We remain committed to investing in further product development and regulatory filings to strengthen our presence in this space of Complex injectables. In our CDMO business, the signing of a 10 year take-or-pay agreement with a Europe-based company in the alternative protein space is at an advanced stage. This potential agreement enables us to significantly expand our bio-manufacturing capacity in a phased manner, aligned with customer requirements and demand visibility. Overall, we remain confident in our growth outlook and the potential of our emerging businesses. We believe our Injectables and CDMO businesses have the potential to scale meaningfully over the coming years and ultimately reach a size comparable to our established API business.” About Symbiotec Pharmalab Limited (‘Symbiotec’) Symbiotec Pharmalab Limited is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology and complex injectables. Founded in 1995, the Company holds a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs). Symbiotec serves over 200 customers across more than 40 countries through three complementary business verticals — APIs, CDMO services and Complex Injectables — supported by four manufacturing facilities in Madhya Pradesh, India, with approvals from USFDA, EU- GMP, WHO-GMP, Japan-PMDA and other leading global regulators. Disclaimer Certain statements contained in this document may be statements of future expectations and other forward- looking statements that are based on management ‘s current view and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. None of Symbiotec Pharmalab Limited or any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its content or otherwise arising in connection with this document. This document does not constitute an offer or invitation to purchase or subscribe for any shares and neither it nor any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. For further information please contact Company Investor Relations Advisors Symbiotec Pharmalab Limited Strategic Growth Advisors Pvt Ltd. CIN No: U24232MP2002PLC015293 CIN No: U74140MH2010PTC204285 Email ID: investorrelations@symbiotec.com Sagar Shroff / Prabjeet Singh Tank Email id: sagar.shroff@sgapl.net / prabjeet.singh@sgapl.net Tel No: +91 98205 19303 / +91 81690 49325